Last update Aug. 17, 2022


Limited compatibility

Unsafe. Moderate/severe adverse effects. Compatible under certain circumstances. Follow-up recommended. Use safer alternative or discontinue breastfeeding from 5 to 7 T ½ . Read Commentary.

An opioid analgesic with a similar structure to methadone indicated for mild to moderate pain relief. Oral administration every 4 hours. It is metabolized to norpropoxyphene, which has a very long elimination half-life (30 to 36 hours).

It is excreted in breastmilk in very small quantities (Mylan 2009, Kunka 1985 and 1984), but potentially serious side effects have been reported (hypotonia, lack of weight gain, apneas, bradycardia, cyanosis) in newborns whose breastfeeding mothers were taking it. (Soasan 2014, Rigourd 2008, Naumburg 1988).

It is believed that this may be due to the slow elimination of the norpropoxyphene metabolite in adults, which is still much slower in newborns, so there may be accumulation in young infants. (Mylan 2009, Spigset 2000)

The American Academy of Pediatrics initially considered it to be a medication which is usually compatible with breastfeeding (AAP 2001). Subsequently, it does not recommend its use during breastfeeding. (Sachs 2013)

During breastfeeding, safer known alternatives are preferable, especially during the neonatal period and in cases of prematurity. It has been withdrawn from sale due to lack of efficacy and potentially serious side effects. (EMA 2010, FDA 2010).


  • Butorphanol Tartrate (Safe substance and/or breastfeeding is the best option.)
  • Ibuprofen (Safe substance and/or breastfeeding is the best option.)
  • Morphine (Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.)
  • Paracetamol (Safe substance and/or breastfeeding is the best option.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Dextropropoxyphene is also known as

Dextropropoxyphene in other languages or writings:


Dextropropoxyphene belongs to this group or family:


Main tradenames from several countries containing Dextropropoxyphene in its composition:


Variable Value Unit
Oral Bioavail. 35 %
Molecular weight 340 daltons
Protein Binding 80 %
VD 16 l/Kg
Tmax 2 - 2.5 hours
6 -12 (Norp: 30 - 36) hours
M/P ratio 0.5 -


  1. Soussan C, Gouraud A, Portolan G, Jean-Pastor MJ, Pecriaux C, Montastruc JL, Damase-Michel C, Lacroix I. Drug-induced adverse reactions via breastfeeding: a descriptive study in the French Pharmacovigilance Database. Eur J Clin Pharmacol. 2014 Abstract
  2. Sachs HC; Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. Pediatrics. 2013 Sep;132(3):e796-809. Abstract Full text (link to original source) Full text (in our servers)
  3. EMA. Questions and answers on the withdrawal of the marketing authorisations for medicines containing dextropropoxyphene. 2010 Full text (link to original source) Full text (in our servers)
  4. FDA Drug Safety Communication. FDA recommends against the continued use of propoxyphene. 2010 Full text (link to original source) Full text (in our servers)
  5. Mylan. Dextropropoxyphene. Drug Summary. 2009 Full text (in our servers)
  6. Rigourd V, Amirouche A, Tasseau A, Kintz P, Serreau R. Retrospective diagnosis of an adverse drug reaction in a breastfed neonate: liquid chromatography-tandem mass spectrometry quantification of dextropropoxyphene and norpropoxyphene in newborn and maternal hair. J Anal Toxicol. 2008 Abstract
  7. Spigset O, Hägg S. Analgesics and breast-feeding: safety considerations. Paediatr Drugs. 2000 Abstract
  8. Naumburg EG, Meny RG. Breast milk opioids and neonatal apnea. Am J Dis Child. 1988 Abstract
  9. Kunka RL, Yong CL, Ladik CF, Bates TR. Liquid chromatographic determination of propoxyphene and norpropoxyphene in plasma and breast milk. J Pharm Sci. 1985 Abstract
  10. Kunka RL, Venkataramanan R, Stern RM, Ladik CF. Excretion of propoxyphene and norpropoxyphene in breast milk. Clin Pharmacol Ther. 1984 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM